What is Nuvation Bio's US — revenue?

Nuvation Bio (NUVB) reported US — revenue of $77.39M in Q1 2026.

What does US — revenue mean?

Represents the total gross income generated from the sale of goods or services within the United States geographic segment. This metric serves as a primary indicator of market penetration and commercial success for the company's therapeutic offerings in the domestic market. It reflects the aggregate value of all recognized revenue streams attributed to US-based operations.

Nuvation Bio NUVB US — Revenue

Similar metrics at other companies

BHEUS — Revenue

$359.62M+10.1%

WORUS — Revenue

$222.86M-3.5%

FBPUS — Revenue

$40.3M+7.3%

RUMUS — Revenue

$22.91M+2.9%

FBINUS — Revenue

$935.53M-1.8%

OLEDUS — Revenue

$4.73M-32.2%

Other financials

Income statement

See full

Revenue$83.2M+2,599%

Gross profit$9.8M+1,340%

Operating income$3.9M+107%

Net income$5.4M+110%

EPS (diluted)$0.01+106%

Balance sheet

See full

Cash & equivalents$125.4M+161%

Total debt$57.2M+401%

Total equity$319.6M-23.8%

Total assets$610.2M+23.9%

Cash flow

See full

Operating cash flow$5.1M+112%

CapEx$48.0K-33.3%

Free cash flow$5.0M+112%

Valuation

See full

Market cap$2.1B+150%

Enterprise value$2.03B+154%

P/S14.7×-62.0×

Profitability

See full

Gross margin54.3%+39.5pp

Operating margin-105%-52.0pp

Net margin-102.1%-50.6pp

FCF margin-93.5%-45.2pp

Returns & leverage

See full

Return on equity-39.5%-15.8pp

Debt / equity0.2×+0.2×

Current ratio7.4×-1.6×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Nuvation Bio’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's us — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Nuvation Bio's US — revenue?: Nuvation Bio (NUVB) reported US — revenue of $77.39M in Q1 2026.
What does US — revenue mean?: Represents the total gross income generated from the sale of goods or services within the United States geographic segment. This metric serves as a primary indicator of market penetration and commercial success for the company's therapeutic offerings in the domestic market. It reflects the aggregate value of all recognized revenue streams attributed to US-based operations.